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Abstract
Abnormalities in uterine contractility are thought to contribute to several clinical problems,
including preterm labor. A better understanding of the mechanisms controlling uterine activity
would make it possible to propose more appropriate and effective management practices than
those currently in use. Recent advances point to a role of the protein kinase C (PRKC) family in
the regulation of uterine smooth muscle contraction at the end of pregnancy. In this review, we
highlight recent work that explores the involvement of individual PRKC isoforms in cellular
process, with an emphasis on the properties of PRKCZ isoform.
Background
During human pregnancy, development and contractile
activity of uterine smooth muscle are regulated by numer-
ous maternal and fetal signals. Steroid hormones, growth
factors, catecholamines, eicosanoids, neuropeptides, and
cytokines have all been implicated in the growth and dif-
ferentiation of the myometrium as well as in its contractil-
ity. The past 17 yr have seen the emergence of a new
potent vasoconstrictor, endothelin-1 (EDN1, abbreviated
as ET-1) that can exert a wide spectrum of biological
actions in many different tissues including uterine
smooth muscle (for a review see [1]). The concentration
of ET-1 in maternal blood is increased during pregnancy
and reaches a peak at term, and its concentration in amni-
otic fluid is also high [2]. Like other uterotonic agents, ET-
1 is effective for stimulating the force and frequency of
human myometrial contractions in vitro. The uterine con-
tractile responsiveness to ET-1 is markedly increased at the
end of pregnancy [3] and is accompanied by an elevation
of the density of myometrial endothelin receptor type A
(EDNRA) receptors functionally coupled to the phosphol-
ipase C (PLC)/calcium system [4,5]. Activation of the
polyphosphoinositide signaling cascade plays a key role
during generation of ET-1-stimulated myometrial contrac-
tions. Among the multigene family of serine/threonine
kinases, the protein kinase C (PRKC) has been shown to
participate to the regulation of uterine smooth muscle
contraction, but species-related differences in PRKC-
mediated signaling have been reported [6-10]. A total of
11 isoforms have been cloned to date, and they are classi-
fied in three groups on the basis of their cofactor require-
ments [11,12] (Figure 1).
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Results and discussion
A role for PRKC in ET-1-induced uterine contraction at the 
end of pregnancy
At least three conventional PRKC isoforms (cPRKC)
(PRKCA, PRKCB1, PRKCB2), two novel PRKC isoforms
(nPRKC) (PRKCD, PRKCE) and an atypical PRKCZ iso-
form were detected in human pregnant myometrium
[13,14].
It seems to be less obvious whether PRKC plays a role in
the kinase cascade involved in the myometrial contractile
process during human pregnancy. We have attempted to
individualize the PRKC isoform able to selectively elicit
uterine contraction at the end of pregnancy. Selective
inhibitors of cPRKC and PRKCD isoforms, do not prevent
ET-1-induced contractions, whereas LY294002, a phosph-
oinositide-3-kinase (PI3K) inhibitor, affects the contrac-
tile response [13,15]. These results suggest but not
demonstrate a role for aPRKC isoforms in myometrial
contractions. We extended the analysis to a complemen-
tary model of cultured myometrial cells, which could be
utilized for identifying potential regulatory pathways that
modulate normal uterine activity. In a functional assay
using collagen gel retraction, we confirmed that human
myometrial cells maintain a smooth muscle cell pheno-
type in culture and responded appropriately to the potent
uterotonic agent, ET-1, via selective activation of the
EDNRA receptor [16]. This technique was therefore uti-
lized to elucidate the precise contribution of the PRKC
pathways in myometrial cell contraction. As shown in Fig-
ure 2, pharmacological inhibition of cPRKC and nPRKC
did not affect myometrial cell contraction. Treatment of
myometrial cell lattices with an inhibitory peptide specific
for PRKCZ or with an antisense-oligonucleotide (AS-
ODN) against PRKCZ resulted in a significant lost of ET-
1-induced contraction. In addition, activated PRKCZ asso-
ciates with the actin component of the cytoskeleton of cul-
tured human pregnant myometrial cells and may regulate
the phosphorylation or binding properties of actin. These
different approaches provide the first evidence that only
Diagrammatic representation of the domain structure of PRKC isoforms Figure 1
Diagrammatic representation of the domain structure of PRKC isoforms. Conventional, cPRKC isoforms (PRKCA, 
PRKCB1, PRKCB2, and PRKCG also known as PRKCα,β1,β2, and γ, respectively) are diacylglycerol (DAG) sensitive and Ca2+ 
responsive (C2 is the Ca2+-binding domain, C1 features the DAG and phosphatidylserine binding; at the N-terminal of the C1 
domain is located a pseudosubstrate site that regulates PRKC activity). Novel, nPRKC isoforms (PRKCD, PRKCE, PRKCH, 
PRKCQ, and PRCKM also known as PRKC δ,ε,η,θ, and μ, respectively) are DAG sensitive but Ca2+ insensitive (the C2-like 
domain do not retain Ca2+-coordinating residues). Atypical, aPRKC isoforms (PRKCZ and PRKCI, also known as PRKC ζ and 
λ, respectively) are regulated by phospholipidic mediators products including phosphatidylinositol 3,4,5-triphosphate). All 
kinases have a conserved kinase core (C4) and a C3 domain, which represents the ATP-binding site (for a review see [12].BMC Pregnancy and Childbirth 2007, 7(Suppl 1):S11 http://www.biomedcentral.com/1471-2393/7/S1/S11
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PRKCZ activation mediated ET-1-induced myometrial
contraction in late pregnancy [15]. In contrast, in one
study, Ozaki et al. [17] reported that PRKC activation by
phorbol ester possibly through PRKCB pathway,
enhances contraction induced by high K+ in the pregnant
human myometrium with increasing Ca2+ sensitivity of
contractile elements, while a report by Bermeo et al. [18]
found that magnesium sulfate and oxytocin require extra-
cellular calcium to induce activation of both PRKCA and
PRKCD in cultured myometrial cells from pregnant
women. The controversial role of PRKC isoforms in uter-
ine contractility required clarification.
Role of aPRKC and NFKB in human myometrial cells
The control of the onset of labor in women is as yet
unknown, but the implication of the PRKCZ in the con-
tractile uterine process at the time of parturition is not so
surprising.
Why? Modulation of the immune/inflammatory mecha-
nisms, specially a balance between T helper (Th1)/Th2
cytokine production, has been described at the time of
parturition, and a link between TNF/IL1B and premature
human childbirth has been proposed [19]. Additionally,
aPRKCs are important components of the TNF/IL1B sign-
aling pathway that control NFKB activation [20-22].
Undoubtedly, it is important to elucidate the probable
interaction between these aPRKC isoforms and the cas-
cade of pro-inflammatory cytokines.
Approximately 20% to 33% of preterm birth is associated
with an underlying infection process. Systemic or local
intrauterine infections have been implicated in the patho-
A-ET-1 induces contraction of collagen lattices by myometrial cells Figure 2
A-ET-1 induces contraction of collagen lattices by myometrial cells. Photographs shown are of free-floating collagen 
lattices in culture dishes (diameter 35 mm). Collagen lattices are shown at time t = 0 (a) and after incubating for 24 h in serum-
free containing 50 nM ET-1 (b). B-Effect of PRKC inhibition on ET-1-promoted gel contraction. Free-floating collagen lattices 
were incubated without (control) or with the cPRKC inhibitor Gö-6976 (0.5 μM), the PRKCD inhibitor Rottlerin (3 μM), the 
inhibitory peptide specific for PRKCZ peptide Z, the antisense oligonucleotide (AS-ODN) (4 μM) or sense (S-ODN) directed 
against PRKCZ before the addition of 50 nM ET-1. Results are expressed as mean percentage contraction ± SE of at least 3 
determinations. *P < 0.05 compared with control.BMC Pregnancy and Childbirth 2007, 7(Suppl 1):S11 http://www.biomedcentral.com/1471-2393/7/S1/S11
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genesis of preterm labor and delivery (for a review, see
[23]). Exposure to microbial insult induces preterm birth
in several animal models. For example in the pregnant
mouse, the endotoxin lipopolysaccharide (LPS) (a glycol-
ipid derived from the outer membrane of gram-negative
bacteria)-enhances amplitude of in vitro spontaneous
uterine contractile activity [24] and premature labor and
delivery can be induced in vivo by both local and systemic
administration of LPS [25-27].
In humans, bacterial vaginosis and intrauterine infection
with Gram-negative are now believed to be an important
factor of risk for preterm labor [28]. The invasion of
microorganisms in the utero-genital sphere triggers a
release of pro-inflammatory cytokines such as TNF/IL1B.
Activation of the cytokine cascade results in the produc-
tion of uterotonic agents leading to parturition. Resident
macrophages are thought to be the principal cell type in
the female genital tract with a receptor-mediated signal
transduction mechanism that is essential for immune
responses to LPS [29].
Further analysis has been conducted on a model of bacte-
rial LPS-induced inflammation of myometrial cells in
order to examine a potential role of PRKCZ in this proc-
ess. This in vitro model using LPS should mimic human
infection-associated preterm labor. Myometrial cells
express TLR4 receptors and have the potential to respond
to LPS. This is further supported by the activation of
PRKCZ by LPS and by the fact that LPS is able to activate
the NFKB pathway. As shown in Figure 3, incubation of
human myometrial cells with AS-ODN to PRKCZ abol-
ished the LPS-induced nuclear translocation of NFKB p65
subunit [30]. It is therefore conceivable that NFKB p65
signalling pathway includes PRKCZ in our cell model.
Unraveling the whole cascade of NFKB activation occur-
ring in myometrial cells remains a difficult challenge. The
enigma becomes complex, because of a switch in NFKB
subunit composition in the human myometrium during
pregnancy and labor [31]. In addition, increased expres-
sion of NFKB in the human myometrium at end of preg-
nancy is involved in functional progesterone withdrawal
[32]. A question arising from these observations is
whether activated NFKB also increases expression of target
genes that cause increased myometrial contractility. One
plausible candidate is the cyclooxygenase-2 (also known
as prostaglandin-endoperoxide synthase 2, PTGS2) that
might be included among the members of the "cassette of
contraction-associated proteins". Recently, Duggan et al.
[33] have established that aPRKCs mediate NFKB tran-
scriptional activation and form part of the signaling net-
work required for IL1B-induced PTGS2 expression in
human cultured myometrial cells.
Conclusion
All these results indicate that the aPRKC-related pathway
is involved in the uterine contractile process at the end of
pregnancy. Future work is needed to elucidate the interac-
tions between aPRKC isoform and the cascade of
cytokines, but the results reported here unveil a novel
mechanism that links aPRKC to inflammatory signaling
in the myometrium. Knowledge of the precise mechanism
of aPRKCs (PRKCZ?) in the cascade of events supporting
the preterm labor in human, will open the development
of novel strategies to prevent premature delivery.
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Inhibition of PRKCZ prevents the nuclear translocation of NFKB p65 subunit induced by LPS in myometrial cells Figure 3
Inhibition of PRKCZ prevents the nuclear translocation of NFKB p65 subunit induced by LPS in myometrial 
cells. Cells were treated without (control) or for 120 min with LPS (10 μg/ml) in the absence or presence of AS-ODN (4 μM) 
directed against human PRKCZmRNA. Cells were fixed, permeabilized and immunostained with antibody against NFKB p65 
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